153 related articles for article (PubMed ID: 8541815)
1. Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol.
Lusuardi M; Capelli A; Salmona M; Tacconi MT; Cerutti CG; Donner CF
Monaldi Arch Chest Dis; 1995 Oct; 50(5):346-51. PubMed ID: 8541815
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol.
Matthys H; de Mey C; Carls C; Ryś A; Geib A; Wittig T
Arzneimittelforschung; 2000 Aug; 50(8):700-11. PubMed ID: 10994153
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of ambroxol in chronic bronchitis.
Guyatt GH; Townsend M; Kazim F; Newhouse MT
Chest; 1987 Oct; 92(4):618-20. PubMed ID: 3308343
[TBL] [Abstract][Full Text] [Related]
4. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters.
Thompson AB; Daughton D; Robbins RA; Ghafouri MA; Oehlerking M; Rennard SI
Am Rev Respir Dis; 1989 Dec; 140(6):1527-37. PubMed ID: 2604284
[TBL] [Abstract][Full Text] [Related]
5. Airways inflammation in subjects with chronic bronchitis who have never smoked.
Lusuardi M; Capelli A; Cerutti CG; Spada EL; Donner CF
Thorax; 1994 Dec; 49(12):1211-6. PubMed ID: 7878554
[TBL] [Abstract][Full Text] [Related]
6. Ambroxol decreases bronchial hyperreactivity.
Melillo G; Cocco G
Eur J Respir Dis; 1986 Nov; 69(5):316-20. PubMed ID: 3539631
[TBL] [Abstract][Full Text] [Related]
7. Lower respiratory tract lactoferrin and lysozyme arise primarily in the airways and are elevated in association with chronic bronchitis.
Thompson AB; Bohling T; Payvandi F; Rennard SI
J Lab Clin Med; 1990 Feb; 115(2):148-58. PubMed ID: 2299262
[TBL] [Abstract][Full Text] [Related]
8. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis.
Linden M; Rasmussen JB; Piitulainen E; Tunek A; Larson M; Tegner H; Venge P; Laitinen LA; Brattsand R
Am Rev Respir Dis; 1993 Nov; 148(5):1226-32. PubMed ID: 8239158
[TBL] [Abstract][Full Text] [Related]
9. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation.
Thompson AB; Mueller MB; Heires AJ; Bohling TL; Daughton D; Yancey SW; Sykes RS; Rennard SI
Am Rev Respir Dis; 1992 Aug; 146(2):389-95. PubMed ID: 1489129
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of efficacy and tolerance of oral treatment with ambroxol in patients with chronic bronchitis].
Michnar M; Milanowski J
Pneumonol Alergol Pol; 1996; 64 Suppl 1():90-6. PubMed ID: 9190245
[TBL] [Abstract][Full Text] [Related]
11. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo.
Olivieri D; Zavattini G; Tomasini G; Daniotti S; Bonsignore G; Ferrara G; Carnimeo N; Chianese R; Catena E; Marcatili S
Respiration; 1987; 51 Suppl 1():42-51. PubMed ID: 3299567
[TBL] [Abstract][Full Text] [Related]
12. Normalization of bronchial exocrine pathology after endobronchial treatment with ambroxol.
Aliperta A; Bellissimo U; Turco D; Antinolfi G
Int J Tissue React; 1986; 8(2):167-74. PubMed ID: 2939036
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of lasolvan in patients with chronic obstructive bronchitis and non-atopic bronchial asthma].
Aleksa VI; Prozorova VK; Mal'tseva NA; Shatikhina LN
Ter Arkh; 2001; 73(3):48-51. PubMed ID: 11417181
[TBL] [Abstract][Full Text] [Related]
14. Antiinflammatory properties of ambroxol.
Beeh KM; Beier J; Esperester A; Paul LD
Eur J Med Res; 2008 Dec; 13(12):557-62. PubMed ID: 19073395
[TBL] [Abstract][Full Text] [Related]
15. Local airways immune modifications induced by oral bacterial extracts in chronic bronchitis.
Lusuardi M; Capelli A; Carli S; Spada EL; Spinazzi A; Donner CF
Chest; 1993 Jun; 103(6):1783-91. PubMed ID: 8404101
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of acute bronchitis treatment in adults--a comparison of Bronchosol® syrup and synthetic preparations with ambroxol. Results of observational study].
Fal AM; Schönknecht K
Wiad Lek; 2015; 68(2):139-44. PubMed ID: 26181148
[TBL] [Abstract][Full Text] [Related]
17. [Value of ambroxol in treatment of bronchial asthma and spastic bronchitis].
Siergiejko Z; Obrzut D; Rogalewska A
Pol Tyg Lek; 1991 May 27-Jun 3; 46(22-23):424-7. PubMed ID: 1669082
[TBL] [Abstract][Full Text] [Related]
18. [The effect of inhaled ambroxol treatment on clinical symptoms and chosen parameters of ventilation in patients with exacerbation of chronic obstructive pulmonary disease patients].
Jahnz-Rózyk K; Kucharczyk A; Chciałowski A; Płusa T
Pol Merkur Lekarski; 2001 Sep; 11(63):239-43. PubMed ID: 11761819
[TBL] [Abstract][Full Text] [Related]
19. Influence of ambroxol on tracheobronchial clearance in simple chronic bronchitis.
Ericsson CH; Juhász J; Mossberg B; Philipson K; Svartengren M; Camner P
Eur J Respir Dis; 1987 Mar; 70(3):163-70. PubMed ID: 3569448
[TBL] [Abstract][Full Text] [Related]
20. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol.
Pfeifer S; Zissel G; Kienast K; Müller-Quernheim J
Eur J Med Res; 1997 Mar; 2(3):129-32. PubMed ID: 9113503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
